Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Sell
33
HOOK Quote, Financials, Valuation and Earnings
Last price:
$0.88
Seasonality move
:
-4.12%
Day range:
$0.87 - $0.88
52-week range:
$0.72 - $2.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.74x
P/B ratio:
0.37x
Volume:
990
Avg. volume:
42.5K
1-year change:
-65.3%
Market cap:
$10.7M
Revenue:
$43.9M
EPS (TTM):
-$5.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HOOK
HOOKIPA Pharma, Inc.
|
$3.4M | -$0.64 | 161.63% | -59.87% | $2.00 |
|
GILD
Gilead Sciences, Inc.
|
$7.5B | $2.14 | 1.21% | 32.99% | $130.76 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HOOK
HOOKIPA Pharma, Inc.
|
$0.88 | $2.00 | $10.7M | -- | $0.00 | 0% | 0.74x |
|
GILD
Gilead Sciences, Inc.
|
$119.36 | $130.76 | $148.1B | 18.49x | $0.79 | 2.63% | 5.16x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.81 | $0.85 | $228.1M | 3.04x | $0.80 | 0% | 3.52x |
|
OGEN
Oragenics, Inc.
|
$0.99 | $2.00 | $810.6K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.22 | $7.00 | $7.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HOOK
HOOKIPA Pharma, Inc.
|
-- | 4.719 | -- | 2.92x |
|
GILD
Gilead Sciences, Inc.
|
53.66% | 0.042 | 18.1% | 1.16x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HOOK
HOOKIPA Pharma, Inc.
|
-- | -$17.5M | -105.09% | -105.43% | -769.81% | $32K |
|
GILD
Gilead Sciences, Inc.
|
$6.2B | $3.5B | 18.17% | 41.48% | 45.34% | $4B |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
HOOKIPA Pharma, Inc. vs. Competitors
-
Which has Higher Returns HOOK or GILD?
Gilead Sciences, Inc. has a net margin of -769.81% compared to HOOKIPA Pharma, Inc.'s net margin of 39.21%. HOOKIPA Pharma, Inc.'s return on equity of -105.43% beat Gilead Sciences, Inc.'s return on equity of 41.48%.
Company Gross Margin Earnings Per Share Invested Capital HOOKHOOKIPA Pharma, Inc.-- -$1.23 $34.1M GILDGilead Sciences, Inc.79.84% $2.43 $46.4B -
What do Analysts Say About HOOK or GILD?
HOOKIPA Pharma, Inc. has a consensus price target of $2.00, signalling upside risk potential of 126.89%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $130.76 which suggests that it could grow by 9.55%. Given that HOOKIPA Pharma, Inc. has higher upside potential than Gilead Sciences, Inc., analysts believe HOOKIPA Pharma, Inc. is more attractive than Gilead Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HOOKHOOKIPA Pharma, Inc.0 1 0 GILDGilead Sciences, Inc.16 8 0 -
Is HOOK or GILD More Risky?
HOOKIPA Pharma, Inc. has a beta of 0.911, which suggesting that the stock is 8.947% less volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.318, suggesting its less volatile than the S&P 500 by 68.175%.
-
Which is a Better Dividend Stock HOOK or GILD?
HOOKIPA Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.63% to investors and pays a quarterly dividend of $0.79 per share. HOOKIPA Pharma, Inc. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 805.23% of its earnings as a dividend.
-
Which has Better Financial Ratios HOOK or GILD?
HOOKIPA Pharma, Inc. quarterly revenues are $2M, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.8B. HOOKIPA Pharma, Inc.'s net income of -$15.4M is lower than Gilead Sciences, Inc.'s net income of $3.1B. Notably, HOOKIPA Pharma, Inc.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 18.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma, Inc. is 0.74x versus 5.16x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOOKHOOKIPA Pharma, Inc.0.74x -- $2M -$15.4M GILDGilead Sciences, Inc.5.16x 18.49x $7.8B $3.1B
-
Which has Higher Returns HOOK or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -769.81% compared to HOOKIPA Pharma, Inc.'s net margin of -255.85%. HOOKIPA Pharma, Inc.'s return on equity of -105.43% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital HOOKHOOKIPA Pharma, Inc.-- -$1.23 $34.1M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About HOOK or NBY?
HOOKIPA Pharma, Inc. has a consensus price target of $2.00, signalling upside risk potential of 126.89%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -53.04%. Given that HOOKIPA Pharma, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe HOOKIPA Pharma, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HOOKHOOKIPA Pharma, Inc.0 1 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is HOOK or NBY More Risky?
HOOKIPA Pharma, Inc. has a beta of 0.911, which suggesting that the stock is 8.947% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock HOOK or NBY?
HOOKIPA Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. HOOKIPA Pharma, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HOOK or NBY?
HOOKIPA Pharma, Inc. quarterly revenues are $2M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. HOOKIPA Pharma, Inc.'s net income of -$15.4M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, HOOKIPA Pharma, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 3.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma, Inc. is 0.74x versus 3.52x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOOKHOOKIPA Pharma, Inc.0.74x -- $2M -$15.4M NBYNovaBay Pharmaceuticals, Inc.3.52x 3.04x $521K -$1.3M
-
Which has Higher Returns HOOK or OGEN?
Oragenics, Inc. has a net margin of -769.81% compared to HOOKIPA Pharma, Inc.'s net margin of --. HOOKIPA Pharma, Inc.'s return on equity of -105.43% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital HOOKHOOKIPA Pharma, Inc.-- -$1.23 $34.1M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About HOOK or OGEN?
HOOKIPA Pharma, Inc. has a consensus price target of $2.00, signalling upside risk potential of 126.89%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 103.05%. Given that HOOKIPA Pharma, Inc. has higher upside potential than Oragenics, Inc., analysts believe HOOKIPA Pharma, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HOOKHOOKIPA Pharma, Inc.0 1 0 OGENOragenics, Inc.1 0 0 -
Is HOOK or OGEN More Risky?
HOOKIPA Pharma, Inc. has a beta of 0.911, which suggesting that the stock is 8.947% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock HOOK or OGEN?
HOOKIPA Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOOKIPA Pharma, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HOOK or OGEN?
HOOKIPA Pharma, Inc. quarterly revenues are $2M, which are larger than Oragenics, Inc. quarterly revenues of --. HOOKIPA Pharma, Inc.'s net income of -$15.4M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, HOOKIPA Pharma, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma, Inc. is 0.74x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOOKHOOKIPA Pharma, Inc.0.74x -- $2M -$15.4M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns HOOK or PTN?
Palatin Technologies has a net margin of -769.81% compared to HOOKIPA Pharma, Inc.'s net margin of --. HOOKIPA Pharma, Inc.'s return on equity of -105.43% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HOOKHOOKIPA Pharma, Inc.-- -$1.23 $34.1M PTNPalatin Technologies-- -- -- -
What do Analysts Say About HOOK or PTN?
HOOKIPA Pharma, Inc. has a consensus price target of $2.00, signalling upside risk potential of 126.89%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than HOOKIPA Pharma, Inc., analysts believe Palatin Technologies is more attractive than HOOKIPA Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HOOKHOOKIPA Pharma, Inc.0 1 0 PTNPalatin Technologies0 0 0 -
Is HOOK or PTN More Risky?
HOOKIPA Pharma, Inc. has a beta of 0.911, which suggesting that the stock is 8.947% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock HOOK or PTN?
HOOKIPA Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOOKIPA Pharma, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HOOK or PTN?
HOOKIPA Pharma, Inc. quarterly revenues are $2M, which are larger than Palatin Technologies quarterly revenues of --. HOOKIPA Pharma, Inc.'s net income of -$15.4M is higher than Palatin Technologies's net income of --. Notably, HOOKIPA Pharma, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma, Inc. is 0.74x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOOKHOOKIPA Pharma, Inc.0.74x -- $2M -$15.4M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns HOOK or TOVX?
Theriva Biologics, Inc. has a net margin of -769.81% compared to HOOKIPA Pharma, Inc.'s net margin of --. HOOKIPA Pharma, Inc.'s return on equity of -105.43% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital HOOKHOOKIPA Pharma, Inc.-- -$1.23 $34.1M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About HOOK or TOVX?
HOOKIPA Pharma, Inc. has a consensus price target of $2.00, signalling upside risk potential of 126.89%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3039.01%. Given that Theriva Biologics, Inc. has higher upside potential than HOOKIPA Pharma, Inc., analysts believe Theriva Biologics, Inc. is more attractive than HOOKIPA Pharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HOOKHOOKIPA Pharma, Inc.0 1 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is HOOK or TOVX More Risky?
HOOKIPA Pharma, Inc. has a beta of 0.911, which suggesting that the stock is 8.947% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock HOOK or TOVX?
HOOKIPA Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOOKIPA Pharma, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HOOK or TOVX?
HOOKIPA Pharma, Inc. quarterly revenues are $2M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. HOOKIPA Pharma, Inc.'s net income of -$15.4M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, HOOKIPA Pharma, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma, Inc. is 0.74x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOOKHOOKIPA Pharma, Inc.0.74x -- $2M -$15.4M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Stock Ideas
Buy
64
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
84
TSAT alert for Dec 10
Telesat Corp. [TSAT] is up 4.4% over the past day.
Sell
6
ODC alert for Dec 10
Oil-Dri Corp. of America [ODC] is up 2.49% over the past day.
Buy
84
PAAS alert for Dec 10
Pan American Silver Corp. [PAAS] is down 0% over the past day.
